Advanced Endometrial Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Advanced Endometrial Cancer pipeline constitutes 25+ key companies continuously working towards developing 25+ Advanced Endometrial Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Advanced Endometrial Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Advanced Endometrial Cancer Market.

The Advanced Endometrial Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Advanced Endometrial Cancer Pipeline Report: https://www.delveinsight.com/sample-request/advanced-endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Advanced Endometrial Cancer treatment therapies with a considerable amount of success over the years.
• Advanced Endometrial Cancer companies working in the treatment market are Incyte Corporation, Byondis, Hutchmed, Sanofi, 3D Medicines (Sichuan) Co. Novartis, AstraZeneca, Merck Sharp & Dohme, Huabo Biopharm Co, Iovance Biotherapeutics, Aadi Bioscience, Inc, Kartos Therapeutics, and others, are developing therapies for the Advanced Endometrial Cancer treatment
• Emerging Advanced Endometrial Cancer therapies in the different phases of clinical trials are- Retifanlimab, Trastuzumab duocarmazine (SYD985), fruquintinib, XL147 (SAR245408), Envafolimab+Lenvatinib, BKM120, Olaparib, Lenvatinib, HB0025:, Lifileucel, nab-sirolimus, Navtemadlin, and others are expected to have a significant impact on the Advanced Endometrial Cancer market in the coming years.
• In November 2025, The U.S. Food and Drug Administration (FDA) has granted approval to the Promega OncoMate® MSI Dx Analysis System as a companion diagnostic to help identify patients with microsatellite stable (MSS; meaning not MSI-high) endometrial carcinoma who may benefit from treatment with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with LENVIMA® (lenvatinib), an orally available multi-receptor tyrosine kinase inhibitor developed by Eisai. This marks the first FDA-approved companion diagnostic from Promega.
• In November 2025, Eisai announced new clinical research highlights in gynecologic oncology at the International Gynecologic Cancer Society (IGCS) 2025 Annual Global Meeting in Cape Town, South Africa. A key presentation includes long-term follow-up results from the Phase 3 Study 309/KEYNOTE-775 trial, which assessed lenvatinib (LENVIMA®), Eisai's orally available multi-targeted tyrosine kinase inhibitor, in combination with pembrolizumab (KEYTRUDA®), Merck's anti-PD-1 therapy, compared with physician's choice of treatment in patients with advanced endometrial carcinoma who had previously received at least one platinum-based therapy. The 5-year follow-up findings will be showcased on November 5 during the Endometrial Cancer Master Session: New Approaches and Metastatic Setting (NCT03517449; Abstract #481). Earlier long-term data were presented at the ESMO Congress 2025, with further insights to be shared at IGCS.
• In June 2025, Genmab A/S (Nasdaq: GMAB) reported new findings from cohort B2 of the Phase 1/2 RAINFOLTM-01 trial assessing rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeting ADC that delivers a TOPO1 inhibitor. With a median on-study follow-up of 7.7 months, treatment with Rina-S at 100 mg/m2 every three weeks demonstrated a confirmed objective response rate (ORR) of 50%, including two complete responses, in heavily pretreated patients with advanced endometrial cancer whose disease progressed after platinum-based chemotherapy and an immune checkpoint inhibitor. The median duration of response had not yet been reached. These results come from the endometrial cancer monotherapy dose-expansion B2 cohort of the RAINFOL-01 trial, which explores the safety and efficacy of Rina-S across solid tumors, and were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Advanced Endometrial Cancer Overview
Advanced endometrial cancer refers to a stage of endometrial (uterine) cancer in which the disease has spread beyond the uterus to nearby tissues, lymph nodes, or distant organs such as the ovaries, abdomen, lungs, or liver. At this stage, the cancer is more difficult to treat and often requires a combination of therapies, including surgery, chemotherapy, radiation, hormonal therapy, or targeted treatments. Advanced endometrial cancer is associated with more aggressive disease behavior and a higher risk of recurrence, making early diagnosis and timely management crucial for better outcomes.

Get a Free Sample PDF Report to know more about Advanced Endometrial Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/advanced-endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Advanced Endometrial Cancer Drugs Under Different Phases of Clinical Development Include:
• Retifanlimab: Incyte Corporation
• Trastuzumab duocarmazine (SYD985): Byondis
• fruquintinib: Hutchmed
• XL147 (SAR245408): Sanofi
• Envafolimab+Lenvatinib: 3D Medicines (Sichuan) Co.
• BKM120: Novartis
• Olaparib: AstraZeneca
• Lenvatinib: Merck Sharp & Dohme
• HB0025: Huabo Biopharm Co
• Lifileucel: Iovance Biotherapeutics
• nab-sirolimus: Aadi Bioscience, Inc
• Navtemadlin: Kartos Therapeutics

Advanced Endometrial Cancer Route of Administration
Advanced Endometrial Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Advanced Endometrial Cancer Molecule Type
Advanced Endometrial Cancer Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Advanced Endometrial Cancer Pipeline Therapeutics Assessment
• Advanced Endometrial Cancer Assessment by Product Type
• Advanced Endometrial Cancer By Stage and Product Type
• Advanced Endometrial Cancer Assessment by Route of Administration
• Advanced Endometrial Cancer By Stage and Route of Administration
• Advanced Endometrial Cancer Assessment by Molecule Type
• Advanced Endometrial Cancer by Stage and Molecule Type

DelveInsight's Advanced Endometrial Cancer Report covers around 25+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Advanced Endometrial Cancer product details are provided in the report. Download the Advanced Endometrial Cancer pipeline report to learn more about the emerging Advanced Endometrial Cancer therapies at:
https://www.delveinsight.com/sample-request/advanced-endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Advanced Endometrial Cancer Therapeutics Market include:
Key companies developing therapies for Advanced Endometrial Cancer are - AstraZeneca, Daiichi Sankyo, Faeth Therapeutics, Hoffmann-La Roche, Merck, Karyopharm Therapeutics, Iovance Biotherapeutics, and others.

Advanced Endometrial Cancer Pipeline Analysis:
The Advanced Endometrial Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Endometrial Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Endometrial Cancer Treatment.
• Advanced Endometrial Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Advanced Endometrial Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Endometrial Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Advanced Endometrial Cancer drugs and therapies-
https://www.delveinsight.com/sample-request/advanced-endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Advanced Endometrial Cancer Pipeline Market Drivers
• Rising Prevalence of Endometrial Cancer, especially among women with obesity, metabolic disorders, and increasing age.
• Growing Adoption of Precision Medicine, boosting demand for targeted therapies and immunotherapies.
• Advancements in Genomic Profiling, enabling identification of actionable mutations such as MSI-H and MMR deficiency.
• Strong R&D Investments by pharmaceutical companies focusing on innovative biologics, antibody-drug conjugates (ADCs), and combination therapies.
• Regulatory Support, including fast-track designations for promising therapies addressing unmet medical needs.

Advanced Endometrial Cancer Pipeline Market Barriers
• High Clinical Trial Failure Rates, due to disease heterogeneity and complex tumor biology.
• Limited Biomarker-Driven Therapies, as not all patients present with actionable molecular targets.
• Significant Treatment Costs, restricting access in low- and middle-income regions.
• Adverse Effects of Current Therapies, impacting patient compliance and long-term treatment uptake.
• Slow Patient Recruitment in clinical trials, especially for late-stage disease.
• Regulatory Challenges, including stringent approval pathways for novel therapies.
• Competition from Established Therapies, which can limit uptake of new drug candidates.

Scope of Advanced Endometrial Cancer Pipeline Drug Insight
• Coverage: Global
• Key Advanced Endometrial Cancer Companies: Incyte Corporation, Byondis, Hutchmed, Sanofi, 3D Medicines (Sichuan) Co. Novartis, AstraZeneca, Merck Sharp & Dohme, Huabo Biopharm Co, Iovance Biotherapeutics, Aadi Bioscience, Inc, Kartos Therapeutics, and others
• Key Advanced Endometrial Cancer Therapies: Retifanlimab, Trastuzumab duocarmazine (SYD985), fruquintinib, XL147 (SAR245408), Envafolimab+Lenvatinib, BKM120, Olaparib, Lenvatinib, HB0025:, Lifileucel, nab-sirolimus, Navtemadlin, and others
• Advanced Endometrial Cancer Therapeutic Assessment: Advanced Endometrial Cancer current marketed and Advanced Endometrial Cancer emerging therapies
• Advanced Endometrial Cancer Market Dynamics: Advanced Endometrial Cancer market drivers and Advanced Endometrial Cancer market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.